LPA and hypertriglyceridemia: Promising ASO for the treatment of hypertriglyceridemia such as olezarsen and for lowering Lp(a) such as pelacarsen are in advanced stages of development, as well as siRNAs such as olpasiran and SLN360 also targeting apolipoprotein(a) and decreasing Lp(a).